Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-02-20
2009-06-30
Hartley, Michael G (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S489000, C424S490000, C424S494000, C424S455000
Reexamination Certificate
active
07553844
ABSTRACT:
The present invention relates to a drug combination capable of conferring therapeutic benefits in the treatment of both AIDS and malaria. In particular, it relates to a drug combination including at least one quinolinic antimalarial compound such as chloroquine or hydroxychloroquine, and at least one inhibitor of the Human Immunodeficiency Virus (HIV) protease enzyme. This drug combination is capable of inhibiting the replication of both HIV andPlasmodiumsp. It also relates to the direct antimalarial effects of the HIV PIs.
REFERENCES:
patent: 5278173 (1994-01-01), Davis
patent: 5668149 (1997-09-01), Oroszlan et al.
patent: 6221400 (2001-04-01), Liversidge et al.
patent: 6265406 (2001-07-01), Patel et al.
patent: 2002/0071863 (2002-06-01), Dong et al.
patent: 2002/0077271 (2002-06-01), Cerami et al.
patent: 2002/0177603 (2002-11-01), Johnson et al.
patent: 2004/0102431 (2004-05-01), Boss
patent: 1 374 867 (2004-01-01), None
patent: WO/92/00145 (1992-02-01), None
patent: WO 97/08180 (1997-03-01), None
Andrey Semenov, Jed E. Olson and Philip J. Rosenthal, Antimalarial Synergy of Cysteine and Aspartic Protease Inhibitors, Antimicrobial Agents and Chemotherapy, vol. 42(9), 2254-2258, 1998.
Johan R. Boelaert, Kirk Sperber and Jacquew Piette, The additive in vitro anti-HIV-1 effect of chloroquine, when combined with zidovudine and hydroxyurea, Biochemical pharmaccology, 61, 1531-1535, 2001.
Savarino, A. t al., The anti-HIV-1 activity of chloroquine.Journal of Clinical Virology, 20:131-135 (2001). Elsevier Science.
Savarino, A., et al., Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity.Aids, 15:2221-2229 (2001). Lippincott Williams & Wilkins.
Savarino, A., et al., Anti-HIV Effects of Chloroquine.Journal of Acquired Immune Deficiency Syndrome, 35(3):223-232 (2004). Lippincott Williams & Wilkins.
Sidhu, A., et al., Chloroquine Resistance inPlasmodium falciparumMalaria Parasites Conferred by pfcrt Mutations.Science, Oct. 4, 298:210-213 (2002).
Savarino, A., et al., Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120.FASEB, Jan. 22, 10.1096/fj.02-0512fje. (2003).
Mammano, F., et al., Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type I Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug.Journal of Virology, 74(18): 8524-8531 (2000).
Nathoo, S., et al., Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance ofPlasmodium facliparum-parasitised erythrocytes.The Lancet, Sep. 27, 362:1039-1041 (2003).
Ward, SA. Bray, PG., Definitive proof for a role of pfmdr 1 in quinoline reistance inPlasmodium falciparum. Drug Resistance Updates, April, 3(2): 80-81 (2000).
Makler, MT, et al., Parasite lactate dehydrogenase as an assay forPlasmodium falciparumdrug sensitivity.Am J Trop Med Hyg., Jun. 48(6):739-741 (1993).
“No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients.” AIDS (London, England) Dec. 1, 2000 vol. 14, No. 17, Schippers, E. F., et al.
“Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers.” British Journal of Clincial Pharmacology, Jun. 2001, Khaliq, U., et al.
“Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1.” Lancet. May 11, 2002, vol. 359, No. 9318, Paton, Nicholas I., et al.
“Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1.” Clinical Therapeutics, Sep.-Oct. 1997 vol. 19, No. 5, Sperber, K., et al.
Clin. Ther., Sep. 1999, vol. 21, p. 1456-1496, Okereke.
Treatment for HIV related inflammation, Treatment Review, May 1995 (No. 18) Abstract.
Hydroxychloroquie=ddl=hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles, AIDS Treatment News, Dec. 3, 1990 (No. 332).
Boelaet, et al. The Additive I Vitro and Anti-HIV-1 Effect of Chloroquine, When Combined with Zidovudine and Hydroxyurea, Biochemical Pharmacology, 2001, vol. 61, pp. 1531-1535.
Chukwuemeka, A Management of HIV-Infected Pregnant Patients in Malaria-Endemic Areas; Therapeutic and Safety Considerations in ConComitant Use of Antiviral and Antimalarial Agents, Clinic Therapeutics, 1999, vol. 21, No. 9, 1999, pp. 1456-1496.
Hartley Michael G
Jarrow Formulas, Inc.
McCarter & English LLP
Samala Jagadishwar R
LandOfFree
Methods for treatment of HIV or malaria using combinations... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of HIV or malaria using combinations..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of HIV or malaria using combinations... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4075957